Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

Moderna (MRNA) shares opened in the green this morning after the U.S. Food and Drug Administration (FDA) approved mFLUSIVA (mRNA-1010), the company’s seasonal influenza vaccine for adults aged 50 and older.

The regulatory announcement makes mFLUSIVA the world’s very first market-cleared mRNA flu vaccine. In total, the pharmaceutical giant now has four FDA-approved products in its portfolio.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.